Cohen Investment Advisors LLC Boosts Holdings in Johnson & Johnson $JNJ

Cohen Investment Advisors LLC raised its holdings in Johnson & Johnson (NYSE:JNJ) by 11.1% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 24,117 shares of the company’s stock after buying an additional 2,418 shares during the quarter. Johnson & Johnson makes up approximately 1.9% of Cohen Investment Advisors LLC’s holdings, making the stock its 21st largest holding. Cohen Investment Advisors LLC’s holdings in Johnson & Johnson were worth $3,684,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in JNJ. Vanguard Group Inc. grew its holdings in shares of Johnson & Johnson by 0.5% during the 1st quarter. Vanguard Group Inc. now owns 233,962,679 shares of the company’s stock worth $38,800,371,000 after purchasing an additional 1,170,120 shares during the period. Northern Trust Corp grew its holdings in shares of Johnson & Johnson by 0.4% during the 1st quarter. Northern Trust Corp now owns 30,943,820 shares of the company’s stock worth $5,131,723,000 after purchasing an additional 130,645 shares during the period. Bank of New York Mellon Corp grew its holdings in shares of Johnson & Johnson by 26.4% during the 1st quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company’s stock worth $3,844,580,000 after purchasing an additional 4,842,582 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in shares of Johnson & Johnson by 3.9% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 18,899,263 shares of the company’s stock worth $3,133,602,000 after purchasing an additional 712,181 shares during the period. Finally, Massachusetts Financial Services Co. MA grew its holdings in shares of Johnson & Johnson by 2.5% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 18,282,410 shares of the company’s stock worth $3,031,955,000 after purchasing an additional 448,666 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $190.66 on Friday. The business’s 50 day moving average is $178.48 and its two-hundred day moving average is $163.76. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $192.10. The firm has a market cap of $459.16 billion, a price-to-earnings ratio of 20.39, a PEG ratio of 2.40 and a beta of 0.40. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The company had revenue of $24.02 billion for the quarter. Analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio is presently 55.61%.

Analyst Ratings Changes

A number of analysts have recently issued reports on the company. Guggenheim upgraded Johnson & Johnson from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $167.00 to $206.00 in a report on Tuesday, September 23rd. Bank of America upped their price target on Johnson & Johnson from $175.00 to $198.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. UBS Group set a $198.00 price target on Johnson & Johnson in a report on Friday, October 3rd. Citigroup upped their price target on Johnson & Johnson from $200.00 to $213.00 and gave the stock a “buy” rating in a report on Tuesday. Finally, Weiss Ratings upgraded Johnson & Johnson from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and eight have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $192.94.

Insider Activity

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 0.16% of the stock is currently owned by insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.